Brief: Inhibrx Biosciences Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts
23/10/2025 23:42
Oct 24 (Reuters) - Inhibrx Biosciences Inc INBX.O: INHIBRX BIOSCIENCES REPORTS POSITIVE TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND PROVIDES UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTS INHIBRX BIOSCIENCES INC - OZEKIBART MEETS PRIMARY ENDPOINT IN CHONDROSARCOMA INHIBRX BIOSCIENCES INC - PLANS TO FILE BLA IN Q2 2026 INHIBRX BIOSCIENCES INC - OZEKIBART REDUCES RISK OF DISEASE PROGRESSION BY 52% INHIBRX BIOSCIENCES INC - 23% RESPONSE RATE AND 92% DISEASE CONTROL RATE Source text: ID:nPn4NYYlna Further company coverage: INBX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibrx Biosciences
See all newsInhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study (updated)
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
NASDAQ RESUMED AT 08:00 AM
Brief: Inhibrx's Inbrx-106 Nearly Doubles Response Rate And Achieves Interim Median Pfs Of 9.6 Months In Phase 2 Hnscc Study
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM